| Literature DB >> 33618912 |
Andrea Nachon-Acosta1, Gustavo Martinez-Mier2, Victor Flores-Gamboa3, Octavio Avila-Mercado3, Indira Morales Garcia4, Carlos Yoldi-Aguirre4, Irais Olivares-Garcia5, Maritza De la Paz-Roman6.
Abstract
BACKGROUND: In December 2019, an outbreak of a novel coronavirus (COVID-19) occurred in China and became pandemic in March 2020. Patients undergoing surgery are a vulnerable risk of COVID-19 exposure/infection. The aim of the study was to determine the characteristics and outcomes of patients undergoing surgery during the COVID-19 pandemic in a third level reference hospital in Mexico.Entities:
Keywords: COVID-19; Complications; Coronavirus; Morbidity; Mortality; Outcomes; SARS-CoV-2; Surgery
Year: 2021 PMID: 33618912 PMCID: PMC7825836 DOI: 10.1016/j.arcmed.2021.01.003
Source DB: PubMed Journal: Arch Med Res ISSN: 0188-4409 Impact factor: 2.235
Demographic and preoperative characteristics of patients (n = 193).
| Variable | Total patients | COVID-19 (+) | COVID-19 (–) | |
|---|---|---|---|---|
| Age, years (mean ± std dev.) | 53.9 ± 14.5 | 50.9 ± 15.1 | 54.3 ± 14.4 | 0.2 |
| Age group | ||||
| <65 years | 140 (72.5%) | 17 (77.3%) | 123 (71.9) | |
| 65–74 years | 43 (22.3%) | 4 (18.2%) | 39 (22.8%) | |
| 75–84 years | 9 (4.7%) | 1 (4.5%) | 8 (4.7%) | |
| >85 years | 1 (0.5%) | 0 | 1 (0.6%) | 0.9 |
| Sex | ||||
| Female | 123 (63.7%) | 9 (40.9%) | 114 (66.7%) | |
| Male | 70 (36.3%) | 13 (59.1%) | 57 (33.3%) | 0.018 |
| Functional Status | ||||
| Independent | 140 (72.5%) | 12 (54.5%) | 128 (74.9%) | |
| Partially dependent | 53 (27.5%) | 10 (45.5%) | 43 (25.1%) | 0.045 |
| ASA class | ||||
| Healthy patient (I) | 9 (4.7%) | 9 (5.3%) | 0 | |
| Mild systemic disease (II) | 99 (51.3%) | 93 (54.4%) | 6 (27.3%) | |
| Severe systemic disease (III) | 75 (38.9%) | 61 (33.7%) | 14 (63.6%) | |
| Severe systemic disease/constant threat to life (IV) | 10 (5.2%) | 8 (4.7%) | 2 (9.1%) | 0.035 |
| Steroid use for chronic condition | ||||
| Yes | 1 (0.5%) | 1 (100%) | 0 | 0.1 |
| Sepsis within 48 h prior to surgery | ||||
| Yes | 53 (27.5) | 15 (68.2%) | 38 (22.7%) | 0.001 |
| Ventilator Dependent | ||||
| Yes | 19 (9.8%) | 6 (27.3%) | 13 (7.6%) | 0.01 |
| Disseminated Cancer | ||||
| Yes | 19 (9.8%) | 0 | 19 (9.8%) | 0.1 |
| Diabetes | ||||
| Yes (Oral Medication) | 62 (32.1%) | 10 (45.5%) | 52 (30.4%) | 0.1 |
| Hypertension | ||||
| Yes | 97 (50.3%) | 11 (50%) | 86 (50.3%) | 0.9 |
| Congestive Heart Failure in 30 d prior to surgery | ||||
| Yes | 8 (4.1%) | 1 (4.5%) | 7 (4.1%) | 0.9 |
| Current Smoker within 1 Year | ||||
| Yes | 24 (12.4%) | 1 (4.5%) | 23 (13.5%) | 0.2 |
| History of Severe COPD | ||||
| Yes | 4 (2.1%) | 0 | 4 (2.3%) | 0.4 |
| Dialysis | ||||
| Yes | 24 (12.4%) | 6 (27.3%) | 18 (10.5%) | 0.03 |
| Acute Renal Failure | ||||
| Yes | 38 (19.8%) | 15 (68.2%) | 23 (13.5%) | 0.0001 |
| Body Mass Index (kg/m2) (mean ± std dev.) | 27.1 ± 5.1 | 26.2 ± 4.6 | 27.2 ± 5.2 | 0.3 |
| Body mass index category | ||||
| Normal (20–25 kg/m2) | 73 (37.8%) | 7 (31.8%) | 66 (38.6%) | |
| Overweight (25–30 kg/m2) | 72 (37.3%) | 10 (45.5%) | 62 (36.3%) | |
| Obesity (>30 kg/m2) | 48 (24.9%) | 5 (22.7%) | 43 (25.1%) | 0.6 |
ASA: American Society of Anesthesiologists; COPD: Chronic Obstructive Pulmonary Disease.
Statistically significant by χ2.
Statistically significant by Fisher's exact.
Principal procedures performed by CPT coding.
| Procedure | Total |
|---|---|
| Procedure (CPT code) | |
| Skin, Subcutaneous tissue (10030–11646) | 3 (1.6%) |
| Under Incision and Drainage Procedures on the Skin, Subcutaneous and Accessory Structures | 3 (100%) |
| Breast (19000–19499) | 23 (11.9%) |
| Mastectomy, modified radical, including axillary lymph nodes | |
| with or without pectoralis minor muscle, but excluding pectoralis major muscle | 18 (78.2%) |
| Musculoskeletal (20100–29999) | 11 (5.7%) |
| Amputation, thigh, through femur, any level; open, circular (guillotine) | 5 (45.4%) |
| Respiratory system (30000–32999) | 4 (2.1%) |
| Decortication, pulmonary | 2 (50%) |
| Hemic and Lymphatic System (38204–38232) | 9 (4.7%) |
| Cervical lymphadenectomy | 6 (66.6%) |
| Mediastinum and Diaphragm (39000–39599) | 2 (1%) |
| Salivary Gland and Ducts (42300–42699) | 2 (1%) |
| Stomach (43500–43999) | 7 (3.6%) |
| Gastrectomy, partial, distal | 4 (57.1%) |
| Intestines except Rectum (44005–44979) | 31 (16.1%) |
| Enterectomy, resection of small intestine; single resection and anastomosis | 7 (22.5%) |
| Rectum (45000–45915) | 5 (2.6%) |
| Proctectomy, combined abdominoperineal | 2 (40%) |
| Anus (46020–46699) | 4 (2.1%) |
| Incision and drainage of ischiorectal or intramural abscess | |
| with fistulectomy or fistulotomy, submuscular, with or without placement of seton | 3 (75%) |
| Liver and Biliary tract (47000–47999) | 16 (8.3%) |
| Cholecystectomy | 5 (31.2%) |
| Pancreas (48000–48999) | 5 (2.6%) |
| Pancreatectomy, proximal subtotal with near-total duodenectomy choledochoenterostomy and duodenojejunostomy (pylorus-sparing, Whipple-type procedure) | 3 (60%) |
| Abdomen, Peritoneum and Omentum (49000–49999) | 39 (20.6%) |
| Removal of tunneled intraperitoneal catheter | 17 (43.5%) |
| Urinary system (50010–53899) | 2 (1%) |
| Uterus (Corpus) (58100–58579) | 13 (6.7%) |
| Total abdominal hysterectomy (corpus and cervix), with or without removal of tube(s), with or without removal of ovary(s); | 10 (76–9%) |
| Ovary (58800–58960) | 9 (4.7%) |
| Laparotomy, for staging or restaging of ovarian, tubal, or primary peritoneal malignancy (second look), with or without omentectomy, peritoneal washing, biopsy of abdominal and pelvic peritoneum, diaphragmatic assessment with pelvic and limited para-aortic lymphadenectomy | 3 (33%) |
| Thyroid (60000–60300) | 8 (4.1%) |
| Thyroidectomy, total or complete | 5 (62.5%) |
CPT: Current Procedural Terminology.
Surgical outcomes in all patients (n = 193).
| Outcome | Total | COVID-19 (+) | COVID-19 (–) | |
|---|---|---|---|---|
| Emergency surgery | 57 (29.5%) | 14 (63.6%) | 43 (25.1% | 0.0001 |
| Length of stay, days (mean ± std dev) | 6.8 ± 7.9 | 10.8 ± 13.4 | 6.2 ± 6.8 | 0.4 (Mann-Whitney) |
| Clavien-Dindo classification of complications | ||||
| No complications | 111 (57.5%) | 4 (18.2%) | 107 (62.6%) | |
| Grade I | 3 (1.6%) | 0 | 3 (1.8%) | |
| Grade II | 19 (9.8%) | 2 (9.1%) | 17 (9.9%) | |
| Grade IIIa | 6 (3.1%) | 2 (9.1%) | 4 (2.3%) | |
| Grade IIIb | 13 (6.7%) | 2 (9.1%) | 11 (6.4%) | |
| Grade IVa | 18 (9.3%) | 3 (13.6%) | 15 (8.8%) | |
| Grade IVb | 7 (3.6%) | 3 (13.6%) | 4 (2.3%) | |
| Grade V (Death) | 16 (8.3%) | 6 (27.3%) | 10 (5.8%) | 0.004 |
| ACS NSQIP complication | ||||
| Any complication | 82 (42.4%) | 18 (81.8%) | 64 (37.4%) | 0.0001 |
| Surgical site infection | 24 (12.4%) | 6 (27.3%) | 18 (10.5%) | 0.037 |
| Postoperative blood transfusion | 67 (34.7%) | 13 (59.1%) | 54 (31.6%) | 0.01 |
| Cardiac complication | 2 (1%) | 1 (4.5%) | 1 (0.6%) | 0.2 |
| Urinary tract infection | 5 (2.6%) | 1 (4.5%) | 4 (2.3%) | 0.5 |
| Venous thromboembolism | 1 (0.5%) | 0 | 1 (0.6%) | 0.1 |
| Renal failure | 26 (13.5%) | 12 (54.5%) | 14 (8.2%) | 0.0001 |
| Sepsis | 53 (27.5%) | 15 (68.2%) | 38 (22.2%) | 0.0001 |
| Reintervention | 18 (9.3%) | 5 (22.7%) | 12 (7.6%) | 0.03 |
| Readmission | 11 (5.7%) | 4 (18.2%) | 7 (4.1%) | 0.02 |
| Respiratory complications | 17 (8.8%) | 12 (54.5%) | 5 (2.9%) | 0.0001 |
| Pneumonia | 12 (6.2%) | 7 (31.8%) | 5 (2.9%) | 0.0001 |
| ARDS | 8 (4.1%) | 8 (100%) | 0 | 0.0001 |
| Unexpected postoperative mechanical ventilation | 10 (5.2%) | 8 (36.4%) | 2 (1.2%) | 0.001 |
| Death | 16 (8.3%) | 6 (27.3%) | 10 (5.8%) | 0.004 |
ACS: American College of Surgeons; NSQIP: National Surgical Quality Improvement Program.
Statistically significant by χ2.
Stastically significant by Fisher's exact.
Figure 1COVID-19 Outcomes Summary.
Preoperative risk factors for COVID-19 (+) infection (n = 193) (Logistic regression).
| COVID-19 (+) patients | ||||||
|---|---|---|---|---|---|---|
| Variable | Univariate analysis | Multivariate analysis | ||||
| Odds ratio | 95% CI | Odds ratio | 95% CI | |||
| Age, years | 0.98 | 0.95–1.01 | 0.2 | |||
| Male Sex | 0.34 | 0.14–0.85 | 0.02 | 0.5 | 0.1–1.4 | 0.2 |
| Functional Status Partially dependent | 2.4 | 1–6.1 | 0.05 | 0.8 | 0.2–2.6 | 0.8 |
| ASA class | 0.9 | 0.1–4.8 | 0.092 | |||
| Steroid use for chronic condition | 0 | 0 | 1 | |||
| Sepsis within 48 h prior to surgery | 0.13 | 0.05–0.35 | 0.0001 | 0.23 | 0.07–0.7 | 0.012 |
| Ventilator Dependent | 0.21 | 0.07–0.65 | 0.007 | 0.93 | 0.2–3.96 | 0.92 |
| Disseminated Cancer | 23.3 × 10(6) | 0 | 0.99 | |||
| Diabetes | 0.52 | 0.21–1.2 | 0.16 | |||
| Hypertension | 1.01 | 0.4–2.4 | 0.99 | |||
| Congestive Heart Failure in 30 d prior to surgery | 0.8 | 0.1–7.6 | 0.92 | |||
| Current Smoker within 1 Year | 3.2 | 0.4–25.4 | 0.25 | |||
| History of Severe COPD | 25.2 × 10(6) | 0 | 0.99 | |||
| Dialysis | 0.31 | 0.1–0.9 | 0.003 | 0.6 | 0.1–2.4 | 0.5 |
| Acute Renal Failure | 0.07 | 0.02–0.19 | 0.0001 | 0.88 | 0.2–2.6 | 0.001 |
| Body Mass Index (kg/m2) (mean ± std dev.) | 0.96 | 0.8–1.05 | 0.38 | |||
| Body mass index category | 1.3 | 0.4–4.3 | 0.6 | |||
ASA: American Society of Anesthesiologists; COPD: Chronic Obstructive Pulmonary Disease; CI: Confidence Interval.
Statistically significant.
Statistically significant variables in univariate analysis that were included in multivariate analysis.
Figure 2COVID- 19 and surgical complications (Logistic regression) ARDS: Acute Respiratory Distress Syndrome ACS NSQIP American College of Surgeons National Quality Improvement Program. *Statistically significant (p <0.05).